Galapagos presents encouraging new data for cd19 car-t candidate glpg5101 in non-hodgkin lymphoma at eha 2024

Mechelen, belgium; june 14, 2024, 22:01 cet; galapagos nv (euronext & nasdaq: glpg) today announced that it will present encouraging new data from the ongoing phase 1/2 atalanta-1 study of cd19 car-t candidate, glpg5101, in relapsed/refractory non-hodgkin lymphoma (r/r nhl) at the annual european hematology association (eha) 2024 hybrid congress. galapagos' product candidate glpg5101 is produced using the company's innovative, decentralized t-cell manufacturing platform.
CAR Ratings Summary
CAR Quant Ranking